Thrombolytic treatment as first option in recurrent tricuspid prosthetic valve thrombosis and Ebstein's anomaly

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 8, Issue 2, 2005, Pages 332-334

  Cáceres Lóriga, Fidel Manuel ^a   Pérez López, Horacio ^a   Santos Garcia, José ^a   Morlans Hernández, Karel ^a   Marrero Mirayaga, María A ^b  

^a Inst Cardiol Cardiovasc Surg   (Cuba)

^b National Center of Clinical Trials   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOKINASE; WARFARIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; DRUG DOSE REGIMEN; EBSTEIN ANOMALY; FEMALE; FIBRINOLYTIC THERAPY; HEART ATRIUM SEPTUM DEFECT; HEART RIGHT VENTRICLE FAILURE; HEART VALVE PROSTHESIS; HOSPITAL ADMISSION; HUMAN; PROSTHESIS FAILURE; RECURRENT DISEASE; THROMBOSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TRICUSPID VALVE DISEASE; TRICUSPID VALVE REGURGITATION;

EID: 27244438027     PISSN: 14821826     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mair DD. Ebstein's anomaly: Natural history and management. J Am Coll Cardiol, 19:1047-1055, 1992.
2. Celermajer DS, Bull C, Till JA. Ebstein's anomaly: Presentation and outcome from fetus to adult. J Am Coll Cardiol, 23:170-175, 1994.
3. Torrado E, Ferriz JA, Prieto MA, Rodríguez JJ, Alvarez JM, Vera A, et al. Thrombolysis of thrombosed heart valve prostheses: presentation of 2 cases and review of the literature. Rev Esp Cardiol, 43:345-351, 1990.
4. López H, Cáceres FM, Morlans K, Fagundo H, González N, Marrero MA, et al. Thrombolytic therapy with recombinant streptokinase for prosthetic valve thrombosis. J Card Surg, 17:387-393, 2002.
5. Lengyel M, Fuster V, Keltai M, Roudaut R, Schulte HD, Seward JB, et al. Guidelines for management of left-side prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on prosthetic valve thrombosis. J Am Coll Cardiol, 30:1521-1526, 1997.
6. Alpert J. The thrombosed prosthetic valve. Current recommendations based on evidence from the literature. J Am Coll Cardiol, 41:659-660, 2003.
7. Lengyel M. Thrombolysis should be regarded as first-line therapy for prosthetic valve thrombosis in the absence of contraindications. J Am Coll Cardiol, 45:325, 2005.
8. Echarte JC, Pedroso J, Hidalgo J, Barrera JD. Trombolisis reiteradas en prótesis tricúspide de Bjork-Shiley. Rev Cubana Cardiol Cir Cardiovasc, 10:44-49, 1996.
9. The TERIMA Group Investigators. Multicenter, randomized, comparative study of recombinant vs. Natural streptokinase in acute myocardial infarct. Thromb Haemost, 82:1605-1609, 1999.
10. Mainet D, del Rosario M, Toruncha A. Similar, more than 6-months persisted, antibody and neutralizing activity responses in patients with acute myocardial infarction treated with recombinant or natural streptokinase. Fibrinolysis & Proteolysis, 12:301-309, 1998.
11. The TERIMA Group Investigators. National Extention of Thrombolytic Treatment with Recombinant Streptokinase in Acute Myocardial Infarct in Cuba. Thromb Haemost, 84:949-954, 2000.
12. Reyes O, Torrens I, Ojalvo AG, Seralena A, Garay HE. Profiling the immune responses of human patients treated with recombinant streptokinase after myocardial infarct. Mol Divers, 8:251-256, 2004.
13. Rodaut R, Lafitte S, Rodaut MF, Courtault C, Perron JM, Jais C, et al. Fibrinolysis of mechanical prosthetic valve thrombosis: a single center study of 127 cases. J Am Coll Cardiol, 41:653-658, 2003.
14. Lengyel M. Management of prosthetic valve thrombosis. J Heart Valve Dis, 13:329-334, 2004.
15. Shapira Y, Herz I, Vaturi M, Porter A, Adler Y, Birnbaum Y, et al. Thrombolysis is an effective and safe therapy in stuck bileaflet mitral valves in the absence of high risk thrombi. J Am Coll Cardiol, 35:1874-1880, 2000.